

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	Ziegler, et al.	Examiner:	Audet, Maury A.
Application No.:	10/530,165	Group Art Unit:	1654
Confirmation No:	5604	Docket:	753-48 PCT/US
Filing Date:	April 4, 2005	Dated:	January 29, 2010
371(c) Date:	August 22, 2005		
For:	SUBSTRATES FOR TAFIa		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of EFS-Web Transmission

I hereby certify that this correspondence is being transmitted to the U.S. Patent and Trademark Office via the Office's electronic filing system.

Dated: January 29, 2010

Signature: Marcy Mancuso/



STATEMENT OF THE SUBSTANCE OF INTERVIEW

Sir:

This statement is being submitted in accordance with M.P.E.P. §713.04 and in response to the Interview Summary which was mailed on December 30, 2009. Accordingly, this Statement of the Substance of the Interview is timely filed on January 29, 2010.

Remarks begin on page 2 of this submission.

REMARKS

Applicants wish to thank Examiner Audet for discussing the above-identified application with the undersigned representative on November 18, 2009, during the telephonic interview conducted on that date. Contrary to the indication in the Interview Summary, the undersigned did not speak with Examiner Audet on or about December 1, 2009.

Moreover, contrary to the indication in the Interview Summary, to the best of the undersigned's recollection, it was claims 1, 7, and 15 which were discussed on November 18, 2009. In particular, on November 18, 2009, the undersigned authorized Examiner Audet to amend claim 7 to be in the same "form" as claim 15 (except for its dependency). Specifically, the undersigned authorized Examiner Audet to amend claim 7 as follows:

7. Compounds according to claim 1, wherein the compounds ~~thereby characterized that they~~ are present as acid addition salts in the form of hydrobromides, hydrochlorides, trifluoroacetates or acetates.

Moreover, on November 18, 2009, the undersigned responded to an inquiry of November 12, 2009, from Examiner Audet, as to why the proviso "provided that the following cases do not occur simultaneously: $R_1 = \text{NHC}(\text{NH})\text{NH}_2$, $R_2 = \text{Z}$ and $(\text{AA}_2) = \text{non-substituted or Boc-substituted L-lysine}$ " appears in claim 1. In particular, on November 18, 2009, the undersigned informed Examiner Audet that the undersigned had been informed by Applicants' counsel abroad that the proviso was added to claim 1 to exclude the compound of Hong et al., "Development of Substrate for Carboxypeptidase-B by Employing Thiaarginine Peptides", Bull. Korean Chem. Soc., Vol. 19, No. 2, 1998, pages 189-193 (the "Hong et al. reference"), which Applicants made of record in an Information Disclosure Statement dated June 28, 2005.

Contrary to the Examiner's comments in the Interview Summary, the undersigned never stated that "negative claim limitations in claim 1" were "not made in view of the art, but rather

Application No. 10/530,165

Statement of the Substance of Interview dated January 29, 2010

Docket No. 753-48 PCT/US


Page 3

made because either they were deemed either inferior or non-working combinations." Furthermore, contrary to the indication in the Interview Summary that "no art" was discussed, the Hong et al. reference was, in fact, discussed.

As indicated in the Interview Summary, no exhibit was shown and no demonstration was conducted.

It is respectfully submitted that this submission provides sufficient detail to satisfy the requirements of M.P.E.P. §713.04. If there are any questions regarding this submission, the undersigned representative may be reached at the number listed below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Andrea Wilkovich", written over a horizontal line.

Andrea M. Wilkovich
Registration No.: 53,773

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700